Stock market today: Stocks fall as investors rotate out of tech into Jackson Hole
Kenvue Inc . (NYSE:KVUE), a $45.6 billion market cap company specialized in perfumes, cosmetics, and other toilet preparations, with impressive gross profit margins of 58%, held its 2025 Annual Meeting of Shareholders on May 22, 2025. According to InvestingPro analysis, the company trades at a relatively high P/E ratio of 43x, though net income is expected to grow this year. The voting results of the meeting were disclosed in an 8-K filing with the Securities and Exchange Commission on Tuesday, May 27, 2025. With annual revenues of $15.3 billion and a Fair Value analysis suggesting the stock is currently overvalued, investors seeking detailed insights can access comprehensive financial analysis through InvestingPro’s exclusive research reports, which cover over 1,400 US stocks.
During the meeting, shareholders elected all 13 director nominees to serve on the company’s Board of Directors until the 2026 Annual Meeting. The directors elected include Richard E. Allison, Jr., Seemantini Godbole, Melanie L. Healey, Sarah Hofstetter, Betsy D. Holden, Erica L. Mann, Larry J. Merlo, Thibaut Mongon, Kathleen M. Pawlus, Kirk L. Perry, Vasant Prabhu, Jeffrey C. Smith, and Michael E. Sneed. The election saw a significant number of votes cast in favor of each nominee, with a notable number of broker non-votes for each candidate.
Additionally, the shareholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. The resolution received a substantial majority of votes in favor, with a smaller proportion against and a minimal number abstaining. Broker non-votes were again noted in this resolution.
The appointment of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for 2025 was also ratified by the shareholders with an overwhelming majority.
The 8-K filing did not include any further proposals or discussions from the annual meeting. The results confirm shareholder confidence in the current management and oversight of Kenvue Inc. The company, formerly known as JNTL, Inc., is incorporated in Delaware and headquartered in Summit, New Jersey.
The information in this article is based on the aforementioned SEC filing. While maintaining a moderate debt level, the company’s current ratio of 0.86 indicates that short-term obligations exceed liquid assets. For deeper insights into Kenvue’s financial health and additional ProTips, explore the complete analysis available on InvestingPro.
In other recent news, Kenvue Inc. reported its first-quarter 2025 earnings, surpassing analysts’ expectations with an adjusted earnings per share (EPS) of $0.24 compared to a forecast of $0.23. The company also exceeded revenue forecasts, reporting $3.74 billion against the anticipated $3.68 billion. Additionally, Kenvue announced the issuance of $750 million in Senior Notes, with the proceeds intended for general corporate purposes. Analyst firm Canaccord Genuity reaffirmed a Buy rating on Kenvue, projecting a 33% upside potential, while Citi increased its price target for the company’s stock to $24.50, maintaining a Neutral rating.
Kenvue’s Self Care brands, including Tylenol, Zyrtec, and Motrin, showed strong performance, although the Skin Health & Beauty segment struggled due to past underinvestment. The company anticipates 2-4% organic sales growth for 2025, with a focus on innovation and supply chain resilience. In a management update, Kenvue announced a new Chief Financial Officer, appointing a former Kellanova (NYSE:K) executive to replace Paul Ruh. Despite these positive developments, the company lowered its EPS guidance for 2025, citing a $150 million tariff impact.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.